Why IRB Oversight Failures Are Common in Multicenter Clinical Trials

Introduction: The Challenges of Multicenter IRB Oversight

Multicenter clinical trials involve multiple investigator sites across regions or countries, increasing complexity in regulatory oversight and ethical review. Institutional Review Boards (IRBs) or Ethics Committees (ECs) are responsible for ensuring participant safety and ethical compliance at each site. Regulatory agencies including the FDA, EMA, and MHRA consistently cite IRB oversight failures in multicenter trials as recurring audit findings.

Common deficiencies include inconsistent review of site submissions, poor tracking of continuing review obligations, and delays in reviewing safety data across sites. These failures jeopardize participant protection and undermine trial integrity, often resulting in major or critical audit observations.

Regulatory Expectations for IRB Oversight in Multicenter Trials

Authorities emphasize strict oversight requirements for IRBs managing multicenter studies:

• Each site must have documented IRB/EC approval before initiation of study activities.
• Continuing review of all sites must be performed at least annually and documented.
• Safety data (SAEs, SUSARs, DSURs) must be reviewed consistently across all sites.
• IRBs must maintain complete meeting minutes and records of site-specific decisions.
• Sponsors must verify IRB oversight adequacy during monitoring and audits.

The ISRCTN Registry highlights the importance of transparency and consistency in multicenter trial oversight, underscoring the role of IRBs in maintaining compliance.

Common Audit Findings on IRB Oversight Failures

1. Inconsistent Site Approvals

Auditors often identify sites that initiated enrollment without documented IRB approval.

2. Delayed Continuing Reviews

Inspection reports frequently cite overdue annual reviews of ongoing studies at multicenter sites.

3. Poor Documentation of Safety Reviews

IRBs are often cited for failing to document reviews of safety reports across all participating sites.

4. Sponsor Oversight Gaps

Sponsors frequently fail to verify the adequacy of IRB oversight across multicenter operations.

Case Study: FDA Audit on Multicenter Oversight Deficiencies

In a Phase III global oncology trial, FDA inspectors observed that several sites began participant enrollment without IRB approval letters filed in the Trial Master File (TMF). Additionally, continuing reviews were overdue for multiple sites. The findings were classified as critical, requiring immediate corrective actions and delaying study progression.

Root Causes of IRB Oversight Failures

Root cause investigations commonly identify:

• Lack of centralized tracking systems for multicenter IRB approvals and reviews.
• Resource constraints within IRBs managing large numbers of sites.
• Poor communication between sites, CROs, and IRBs regarding submissions and approvals.
• Weak sponsor oversight of site-level IRB compliance.
• Absence of SOPs addressing multicenter IRB oversight complexities.